BioSpace News Archive

Allergan plc reported its full-year and fourth quarter 2019 financial results including full-year 2019 GAAP net revenues of $16.1 billion, a 1.9 percent increase from 2018.

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced its intention to offer, subject to market and other conditions, $125,000,000 aggregate principal amount of convertible senior notes due 2026 (the “notes”) in a public offering registered under the Securities Act of 1933, as amended.

SAN CARLOS, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced the initiation of a phase 2b clinical trial of its orally administered small molecule CCR3 inhibitor, AKST4290. The company has dosed the first subject in AKST4290-205 (PHTHALO), which will assess the effects of AKST4290 on visual acuity with loading doses of anti-VEGF in treatm

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, is presenting new data from two of its development programs at Keystone Symposia’s Engineering the Genome Conference, a joint meeting with the Emerging Cellular Therapies: Cancer and Beyond Conference, taking place Feb. 8-12, 2020, in Banff, Canada.

MacroGenics, Inc. announced that the Company’s management will attend the following investor conferences in February

[10-February-2020] NEW HAVEN, Conn. , Feb. 10, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that Clarivate Analytics plc (NYSE: CCC; CCC.WS), a global leader in providing trusted insights and analytics to accelerate the pace of innovation, has named rimegepant to its annual Cortellis “Drugs to Watch” list, which identifies 11 new drugs scheduled

Radiology Imaging Associates, PC added 17 physicians and seven employees from Rocky Mountain Radiologists, PC to the RIA practice on January 1, 2020.

First and only FDA-approved oral treatment of its kind for testosterone deficiency 1,2 NORTHBROOK, Ill., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced that JATENZO ® (testosterone undecanoate) capsules, CIII is now available by prescription in the U.S. for the treatment of appropriate men with testosterone deficiency (hypogonadism). JATENZO is the first and only oral softgel testosterone undecanoate, and the first oral testosterone medicine approved by the U.S

Tenon Medical, Inc., a manufacturer of instruments and implants for sacroiliac joint fusion surgery, today announced the completion of the first phase of its post-approval clinical study for the Catamaran™ Sacroiliac Joint Fixation System (CAT SIJ Fixation System) specifically indicated for sacroiliac joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroilitis.

Pharmacosmos Therapeutics Inc. announced today that it has been established as a newly formed specialty pharmaceutical company dedicated to commercializing Monoferric® for Iron Deficiency Anemia (IDA) patients in the US. The new company is a subsidiary of the Pharmacosmos Group, a profitable, fast-growing specialty pharmaceutica